Moreover, our study shows that stable patients with IPF (18 on pirfenidone and 7 on nintedanib) had a significant decrease in the EBC levels of both IL-25 and TSLP after one year of antifibrotic therapy. Here, TSLP is linked to idiopathic pulmonary fibrosis.